News
-
-
PRESS RELEASE
Tharimmune Presents Positive Clinical Data at AASLD the Liver Meeting(R) to Support TH104 for Chronic Pruritus in Chronic Liver Disease
Tharimmune, Inc. presents promising Phase 1 TH104 clinical data at The Liver Meeting® 2024, demonstrating significant correlation between blood levels and symptom relief in chronic liver disease patients -
-
PRESS RELEASE
Tharimmune Granted European Patent for Delivery of Optimized Molecularly Targeted Therapeutics
Tharimmune, Inc. announces the European Patent Office intends to grant a patent for biodegradable polymeric nanoparticles designed to enhance therapeutic delivery in cancer therapies. The innovative platform aims to reduce side effects and improve therapy effectiveness -
-
-
-
PRESS RELEASE
Tharimmune Receives Positive Regulatory Feedback From EMA for TH104 Clinical Program for Chronic Pruritus in Primary Biliary Cholangitis
Tharimmune, Inc. receives positive feedback from EMA on Phase 2 trial plans for TH104, a clinical candidate for pruritus in PBC, a rare liver disease -
-
PRESS RELEASE
Tharimmune Presents Favorable TH104 Phase 1 Clinical Data at the American College of Gastroenterology 2024 Annual Scientific Meeting
Tharimmune presents positive Phase 1 data for TH104 in treating pruritus in chronic liver disease patients at ACG 2024. No opioid withdrawal effects observed, supporting safety profile
